




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07D 285/10, 417/12, A61K 31/41, 31/44		A1	(11) International Publication Number: WO 00/51999 (43) International Publication Date: 8 September 2000 (08.09.00)
(21) International Application Number:	PCT/US00/05240		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date:	1 March 2000 (01.03.00)		
(30) Priority Data:	09/261,343	3 March 1999 (03.03.99)	US
(71) Applicant:	AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).		
(72) Inventors:	SABB, Annmarie, Louise; 15 Meadow Lane, Pennington, NJ 08534 (US). VOGEL, Robert, Lewis; 20 Sleepy Hollow Road, Stratford, NJ 08084 (US). KELLY, Michael, Gerard; 88 Beatty Place, Newbury Park, CA 91320 (US). PALMER, Yvette, Latko; 106 North Main Street, Yardley, PA 19067 (US). CHILDEERS, Wayne, Everett; 5 Vicar Lane, Levittown, PA 19054 (US).		Published <i>With international search report.</i>
(74) Agents:	ECK, Steven, R.; American Home Products Corporation, Patent Law Dept. – 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.		

(54) Title: NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS



(1)

(57) Abstract

The present invention provides compounds of general formula (1) wherein: two atoms of X, Y, or Z are nitrogen and the third atom is sulfur or oxygen; R is H, halogen, OH, SH, C₁–C₆ alkyl, C₁–C₆ alkoxy, C₁–C₆ thioalkyl, phenoxy, thiophenoxy, phenyl or substituted phenyl; A is C, CH, or N; R₁ is aryl, heteroaryl, or cycloalkyl groups, optionally substituted by from 1 to 3 substituents selected from C₁–C₆ alkyl, C₁–C₆ alkoxy, CF₃, Cl, Br, F, CN, or CO₂CH₃; R₂ is H or alkyl; R₃ is C₁–C₆ alkyl, optionally substituted aryl, optionally substituted 5- or 6-membered heteroaryl, C₃ to C₈ cycloalkyl optionally substituted by C₁–C₆ alkyl, or a 3 to 8-membered heterocyclic ring containing one or more heteroatoms selected from O, S or N; or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions and methods of treating central nervous system disorders using these compounds.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NEW DIAZOLE DERIVATIVES AS SEROTONERGIC AGENTS

This invention relates to a series of novel diazolepiperazine, diazolepiperidine, and diazoledihdropiperidine derivatives, and to processes for their preparation, to 5 pharmaceutical compositions containing them, and to their use in therapies concerning central nervous system disorders. These compounds are useful for treatment of conditions related to or affected by the 5-hydroxytryptamine-1-A (5-HT1A) receptor subtype in the CNS, including alcohol and drug withdrawal, sexual dysfunction, and Alzheimer's Disease. The utility of these compounds lies in their 10 ability to bind as agonists and antagonists to 5-HT1A receptors. The compounds of the present invention are also useful in the treatment of depression and related CNS disorders (e.g., OCD, anxiety and panic) when combined with the use of serotonin reuptake inhibitors, such as Prozac[®] (fluoxetine hydrochloride).

15

Background of the Invention

Depression is a psychiatric condition thought to be associated with decreased serotonin release. Most antidepressant agents potentiate the effects of serotonin by blocking the termination of its activity through re-uptake into nerve terminals.

20

United States Patent 3,655,663 (B.K. Wasson, Apr. 11, 1972) covers 4-(3-secondary amino-2-hydroxypropoxy)-1,2,5-thiadiazoles which exhibit beta-adrenergic blocking properties useful for treatment of angina pectoris. Compounds of the present invention are structurally different from this prior art and are useful for 25 treatment of CNS disorders.

WO 96/38431 (Eli Lilly, May 31, 1996) covers methods of making 1,2,5-thiadiazoles containing azacyclic or azabicyclic ether or thioether substituents for use as muscarinic cholinergic agonists. These compounds are useful as stimulants of the 30 forebrain and hippocampus for treatment of Alzheimer's disease. Compounds of this


- 2 -

invention are structurally different from these compounds and are agonists and antagonists of the 5HT1A receptor, not muscarinic agonists.

Summary of the Invention

5

Compounds of the present invention are represented by the general formula (1):



(1)

10 wherein:

the dotted line represents an optional bond;

two atoms of X, Y, or Z are nitrogen and the third atom is sulfur or oxygen;

15 R is H, halogen, OH, SH, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ thioalkyl, phenoxy, thiophenoxy, or phenyl, the phenyl ring being optionally substituted by from one to three substituents selected from C₁-C₆ alkyl; C₁-C₆ alkoxy; CF₃; Cl; Br; F; CN; or CO₂CH₃;

A is C, CH, or N;

R₁ is aryl, heteroaryl, or cycloalkyl groups, the aryl, heteroaryl or cycloalkyl groups being optionally substituted by from 1 to 3 substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy; CF₃, Cl, Br, F, CN, or CO₂CH₃;

R₂ is H or C₁-C₆ alkyl;

20 R₃ is C₁-C₆ alkyl, aryl, 5- or 6-membered heteroaryl, C₃ to C₈ cycloalkyl, the cycloalkyl groups being optionally substituted by C₁-C₆ alkyl, or a 3 to 8-membered

- 3 -

heterocyclic ring containing one or more heteroatoms selected from O, S or N, the aryl and 5- or 6-membered heteroaryl groups being optionally substituted by from one to three substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, CF₃, Cl, Br, F, CN, or CO₂CH₃;


5 or a pharmaceutically acceptable salt thereof.

Heteroaryl groups have one to three heteroatoms selected from oxygen, nitrogen and sulphur.

10 As used herein, the term alkyl refers to C₁-C₆ straight or branched chain, and wherein the term cycloalkyl refers to C₃ to C₈ ring, preferably a C₃ to C₆ ring, or an alkyl-substituted ring. The term "aryl" is phenyl or substituted phenyl, biphenyl, 1 or 2-naphthyl and "heteroaryl" refers to 5 or 6 membered ring heterocycles or benzofused heterocycles, specifically including, but not limited to, thiazole, 15 thiophene, 2, 3, or 4-pyridyl, benzothiophene, or indole. The aryl or heteroaryl groups herein can be optionally substituted with one to three substituents selected from the group consisting of C₁-C₆ alkyl; C₁-C₆ alkoxy; CF₃; Cl; Br; F; CN; CO₂CH₃.

Among the preferred compounds of this invention are those of formula (2):

20



(2)

wherein R, R₁, R₂, and R₃, are as defined above, or a pharmaceutically acceptable salt thereof.

Further preferred are those compounds of formula (1) or formula (2) wherein:

5 R is H, halogen, OH, SH, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ thioalkyl; and/or
R₁ is aryl, heteroaryl or cycloalkyl groups, optionally substituted by from 1 to
3 substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy; CF₃, Cl, Br, F, CN, or
CO₂CH₃; and/or
R₂ is H or C₁-C₆ alkyl; and/or
10 R₃ is C₁-C₆ alkyl, optionally substituted aryl, optionally substituted 5- or 6-
membered heteroaryl, C₃ to C₈ cycloalkyl optionally substituted by C₁-C₆ alkyl, or a 3
to 8-membered heterocyclic ring containing one or more heteroatoms selected from
O, S or N;
or a pharmaceutically acceptable salt thereof.

15 The pharmaceutically acceptable salts are the acid addition salts which can be
formed from a compound of the above general formula and a pharmaceutically
acceptable acid such as phosphoric, sulfuric, hydrochloric, hydrobromic, citric,
maleic, fumaric, acetic, lactic or methanesulfonic acid.

20 The compounds of formula I can possess at least one asymmetric centre and
accordingly the compounds may exist and be isolated in a number of optically active
stereoisomeric forms. This invention encompasses the compounds of formula I in any
optically active form or mixtures thereof, e.g. racemates. Standard separation
25 techniques may be used to isolate particular enantiomeric or diastereomeric forms. For
example a racemic mixture may be converted to a mixture of optically active
diastereoisomers by reaction with a single enantiomer of a 'resolving agent' (for
example by diastereomeric salt formation or formation of a covalent bond). The
resulting mixture of optically active diastereoisomers may be separated by standard

techniques (e.g. crystallisation or chromatography) and individual optically active diastereoisomers then treated to remove the 'resolving agent' thereby releasing the single enantiomer of the compound of the invention. Chiral chromatography (using a chiral support, eluent or ion pairing agent) may also be used to separate enantiomeric
5 mixtures directly.

Detailed Description of the Invention

The compounds of this invention possess high affinity for the serotonin 5-HT_{1A} receptor and, consequently, are useful as antidepressant and anxiolytic agents for the treatment in a mammal of a variety of central nervous system (CNS) disorders such as depression, anxiety, sleep disorders, sexual dysfunction, alcohol and/or cocaine addiction, and related problems. The compounds of this invention may also be used in the inducement of cognition enhancement in a mammal, preferably in
10 humans. In addition, the compounds of this invention show marked selectivity for the 5-HT_{1A} receptors, as opposed to the α 1 receptors.
15

In view of their receptor binding, these compounds may be characterized as anxiolytic and/or antidepressant agents useful in the treatment of depression and in
20 alleviating anxiety. As such, the compounds may be administered neat or with a pharmaceutical carrier or excipient to a patient in need thereof. The pharmaceutical carrier may be solid or liquid.

It is understood that the therapeutically effective dosage to be used in the
25 treatment of a specific psychosis must be subjectively determined by the attending physician. Variables involved include the specific psychosis or state of anxiety and the size, age and response pattern of the patient. The novel methods of the invention for treating, preventing or alleviating conditions as described above, or for inducing cognition enhancement, comprise administering to mammals in need thereof,

including humans, an effective amount of one or more compounds of this invention or a non-toxic, pharmaceutically acceptable addition salt thereof. The compounds may be administered orally, rectally, parenterally, or topically to the skin and mucosa. The usual daily dose is depending on the specific compound, method of treatment and 5 condition treated. An effective dose of 0.01 - 1000mg/Kg may be used for oral application, preferably 0.5 - 500 mg/Kg, and an effective amount of 0.1 - 100 mg/Kg may be used for parenteral application, preferably 0.5 - 50 mg/Kg. It will be understood that in combination with other agonists or antagonists of the serotonin-1 receptor (5-HT₁A), such as those listed above, the effective dose of the present 10 compounds may be reduced relative to the effective amount of the combined active ingredient(s).

The present invention also includes pharmaceutical compositions containing a compound of this invention, or a pharmaceutically acceptable salt thereof, and one or 15 more pharmaceutically acceptable carriers or excipients. Applicable solid carriers or excipients can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintergrating agents or an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the finely divided active 20 ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl 25 cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers may be used in preparing solutions, suspensions, emulsions, 30 syrups and elixirs. The active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic

solvent, a mixture of both or pharmaceutically acceptable oils or fat. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators.

5 Suitable examples of liquid carriers for oral and parenteral administration include water (particularly containing additives as above e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols e.g. glycols) and their derivatives, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration the carrier can also be an
10 oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.

15 Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.


20 Preferably the pharmaceutical compositions and combination compositions of this invention are in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

25

This invention also provides a process for preparing compounds of formula
(1) which process comprises:

a) acylating a compound of formula (3)

- 8 -



(3)

wherein the dotted line R, R₁, R₂, X, Y, Z and A are as defined above, with a compound of formula:



5 (4)

or a reactive derivative thereof (e.g. acid halide such as the chloride or a mixed anhydride) wherein R₃ is as defined above;

or

10 b) converting a basic compound of formula (1) to a pharmaceutically acceptable acid addition salt thereof.


Compounds of the present invention may be prepared by those skilled in the art of organic synthesis employing conventional methods which utilize readily available reagents and starting materials. The methods for preparing compounds of 15 this invention will be further understood from the reaction schemes herein.

Referring to Scheme 1, the requisite dichlorodiazole is allowed to react with 20 tert-butyl carboxy (BOC)-protected piperazine in an organic solvent, such as dimethylformamide (DMF) at elevated temperature under a nitrogen atmosphere to give the corresponding BOC-protected diazolepiperazines **I**. Treatment of the protected piperazines **I** with an acid such as hydrochloric acid, in an inert solvent, such as dioxane, under an inert atmosphere gives the deprotected piperazines **II**. Reaction of the diazolepiperazines **II** with nitrogen-protected amino acids, such as N-

BOC-protected amino acids, in an organic solvent, such as methylene chloride, at room temperature under an inert atmosphere in the presence of an organic base, such as triethylamine (TEA), and a coupling reagent such as cyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBT) forms the amides **III**. Stirring the amides 5 **III** with an acid, such as hydrochloric acid, in an organic solvent, such as dioxane, at room temperature under an inert atmosphere gives the amino amides **IV**. Reduction of the amides with diborane in an organic solvent, such as tetrahydrofuran (THF) gives the corresponding amines **V**. Acylation of the terminal amine with an acylating agent, such as an acyl halide or coupling of the amine with a carboxylic acid gives 10 products of this invention **VI**.

- 10 -

Scheme 1




Referring to Scheme 2, the requisite chlorodiazolepiperazine **II**, is allowed to react with a metal, such as sodium, in a polar solvent, such as methanol, at elevated temperatures under an inert atmosphere to give diazolepiperazine derivatives **VII**.

Allowing these piperazines **VII** to react with an N- BOC-protected amino acid and a coupling reagent, such as DCC in the presence of HOBT and a base, such as TEA, in an organic solvent, such as methylene chloride, gives the amides **VIII**. Stirring the amides **VIII** with an acid, such as hydrochloric acid, in an organic solvent, such as 5 dioxane, gives the amino amides **IX**. Reduction of the amino amides **IX** with diborane in an organic solvent, such as THF, under an inert atmosphere, at elevated temperature gives the amines **X**. Acylation of the terminal amine with an acylating agent, such as an acyl halide, or coupling of the amines with a carboxylic acid gives products of this invention **XI**.

- 12 -


Scheme 2



Referring to Scheme 3, the requisite chlorodiazolepiperazine amide III is allowed to react with a metal, such as sodium, in a polar solvent, such as methanol, at elevated temperatures under an inert atmosphere to give diazolepiperazine derivatives **VIII**. Stirring the amides **VIII** with an acid, such as hydrochloric acid, in an organic solvent, such as dioxane, gives the amino amides **IX**. Reduction of the amino amides **IX** with diborane in an organic solvent, such as THF, under an inert atmosphere, at elevated temperature gives the amines **X**. Acylation of the terminal amine with an acylating agent, such as an acyl halide, or coupling of the amines with 5 a carboxylic acid gives products of this invention **XI**.

10

Scheme 3




Referring to Scheme 4, the N-protected 4-acylpiperidine or N-protected -4-acyldihydropiperidine is added to carbethoxyhydrazine in a polar solvent, such as methanol, at a low temperature, such as 0-5°C, and then heated under reflux to give the hydrazones **XII**. The hydrazones **XII** are heated from 30-100 °C in the presence of thionyl chloride to give 1,2,3-thiadiazole derivatives **XIII**. Deprotection of **XIII** gives the secondary amines **XIV**. Reaction of **XIV** with N-protected amino alcohols containing a leaving group, such as tosylate, in a polar solvent, such as

- 14 -

dimethylsulfoxide, at elevated temperatures, such as 30-100°C, gives N-protected amine intermediates **XV**. Removal of the protecting group gives **XVI** and reaction of **XVI** with an acylating agent or with a carboxylic acid and a coupling reagent such as DCC gives compounds of this invention **XVII**.

- 15 -

Scheme 4




Referring to Scheme 5, 4-substituted pyridines **XVIII** which can be prepared by known methods [Per Sauerberg, et al. *J. Med. Chem.* **1992** *35*, 2274-2283] are 5 protected on nitrogen by a group which can be removed, such as the N-carbethoxy

- 16 -

group, to give **XIX**. **XIX** is reduced to **XX** using a reducing agent, such as NaBH_4 . The protecting group is removed [for the BOC group an acid such as hydrogen chloride can be used] to give **XXI** which is allowed to react with an N-protected amino acid, such as a BOC-protected amino acid, to give amides **XXII**. Removal of the 5 protecting group, such as treatment of the BOC group with an acid such as hydrogen chloride, gives **XXIII**. Reduction of the amides **XXIII** with a reducing agent such as diborane in an organic solvent such as tetrahydrofuran, gives **XXIV**. Acylation of **XXIV** with acylating agents or reaction of **XXIV** with carboxylic acids and a coupling agent such as DCC gives compounds of this invention **XXV**

- 17 -

Scheme 5



5-HT1A Receptor Binding Assay

5 High affinity for the serotonin 5-HT1A receptor was established by testing the claimed compound's ability to displace [³H] 8-OH-DPAT binding in CHO cells stably transfected with the human 5HT1A receptor. Stably transfected CHO cells are grown in DMEM containing 10% heat inactivated FBS and non-essential amino acids. Cells are scraped off the plate, transferred to centrifuge tubes, and washed

twice by centrifugation (2000 rpm for 10 min., 4°C) in buffer (50 mM Tris pH 7.5). The resulting pellets are aliquoted and placed at -80°C. On the day of assay, the cells are thawed on ice and resuspended in buffer. The binding assay is performed in a 96 well microtiter plate in a total volume of 250 mL. Non-specific binding is determined 5 in the presence of 10 mM 5-HT, final ligand concentration is 1.5 nM. Following a 30 minute incubation at room temperature, the reaction is terminated by the addition of ice cold buffer and rapid filtration through a GF/B filter presoaked for 30 minutes in 0.5% PEI. Compounds are initially tested in a single point assay to determine percent inhibition at 1, 0.1, and 0.01 mM, and Ki values are determined for the active 10 compounds.

5-HT1A Receptor Intrinsic Activity Assay

The intrinsic activity of compounds of the present invention was established 15 by testing the claimed compounds ability to reverse the stimulation of cyclic adenosinemonophosphate (cAMP) in CHO cells stably transfected with the human 5-HT1A receptor.

Stably transfected CHO cells were grown in DMEM containing 10% heat inactivated 20 FBS and non-essential amino acids. The cells are plated at a density of $\times 10^6$ cells per well in a 24 well plate and incubated for 2 days in a CO₂ incubator. On the second day, the media is replaced with 0.5 mL treatment buffer (DMEM + 25 mM HEPES, 5 mM theophylline, 10 mM pargyline) and incubated for 10 minutes at 37°C. Wells are treated with forskolin (1 mM final concentration) followed immediately by the test 25 compound (0.1 and 1 mM for initial screen) and incubated for an additional 10 minutes at 37°C. The reaction is terminated by removal of the media and addition of 0.5 mL ice cold assay buffer (supplied in the RIA kit). Plates are stored at -20°C prior to assessment of cAMP formation by RIA. EC₅₀ values are determined for the active test compounds. Compounds shown to have no agonist activities (Emax = 0 30 %) are further analyzed for their ability to reverse agonist induced activity. In

- 19 -

separate experiments, 6 concentrations of antagonist are preincubated for 20 minutes prior to the addition of agonist and forskolin. Cells are harvested as described above. The cAMP kit is supplied by Amersham and the RIA is performed as per kit instructions, and calculations of IC_{50} performed by GraphPad Prism.

5

	Compound	5-HT1A binding	cAMP
		Ki (nM)	Emax
	Compound 4	0.84	93.00 ($EC_{50} = 4.61$.nM)
	Compound 5	425.20	
10	Compound 6	47% @ 1 μ M	
	Compound 7	4.55	0.00 ($IC_{50} = 49.26$ nM)
	Compound 8	1.55	0.00 ($IC_{50} = 72.74$ nM)
	Compound 9	9.87	
	Compound 11	3.04	0.000 ($IC_{50} = 113.00$ nM)

15

The following non-limiting specific examples are included to illustrate the synthetic procedures used for preparing compounds of the formula 1. In these examples, all chemicals and intermediates are either commercially available or can be prepared by standard procedures found in the literature or are known to those skilled 20 in the art of organic synthesis. Several preferred, non-limiting embodiments are described to illustrate the invention.

Example 1

1-(4-Chloro-[1,2,5]thiadiazol-3-yl)piperazine Hydrochloride

25

Piperazine-1-carboxylic acid tert-butyl ester (10 g, 0.054 m) was dissolved in anhydrous dimethylformamide (DMF, 50 mL) under nitrogen in a single-necked round bottomed flask. The clear solution was placed in a preheated oil bath (50°C - 60°C). 4,5-Dichloro-[1,2,5]thiadiazole (5.0 mL, 0.054 m) was added and the reaction 30 mixture was allowed to stir for 24 h. A yellow solution containing a white solid was

- 20 -

observed. After cooling to room temperature, the mixture was diluted with an equal volume of anhydrous ethyl ether and stirred for 5 minutes. The solid was removed by filtration and the yellow filtrate was concentrated under aspirator vacuum to remove ether and then evaporated under oil pump vacuum to remove DMF. The yellow residue was dried at oil pump vacuum overnight to give 9.91 g of 4-(4-chloro-[1,2,5]thiadiazol-3-yl)piperazine-1-carboxylic acid tert-butyl ester. Two recrystallizations of crude product from hexane gave white crystals: mp 83-86 °C

Anal. Calcd for $C_{11}H_{17}ClN_4O_2S$. 0.075 mol hexane:

Theory: % C, 44.18; % H, 5.85; % N, 18.00

10 Found: % C, 44.44; % H, 5.84; %N, 17.80

The tert-butyl ester I (400 mg, 1.3 mmol) was treated with 4N HCl (5.0 mL) in dioxane under a nitrogen atmosphere. The ester dissolved and a white precipitate formed gradually. The mixture was allowed to stir overnight at room temperature. 15 The reaction mixture was diluted with heptane and filtered to collect a crystalline solid which was rinsed with heptane and dried to give 285 mg of the title compound as a pale yellow solid, mp: 205 °C (dec).

Anal. Calcd. for $C_6H_9ClN_4S$. HCl. 0.15 H_2O

20 Theory: % C, 29.56; % N, 4.26; % N, 22.98

Found: % C, 29.99; % N, 4.40; % N, 22.34

Example 2

4-Piperazin-1-yl-[1,2,5]thiadiazole-3-ol Hydrochloride

25

The title compound of example 1 (1.25 g, 5.18 mmol), was combined with 2.5 N NaOH (10 mL) and dimethylsulfoxide (DMSO, 1.0 mL) and heated under reflux with stirring for 2.5 h. The heat was shut off and the cloudy mixture was allowed to cool and stir overnight. The pale yellow solution was chilled in an ice bath and acidified to pH 0 with concentrated HCl. The mixture was chilled in an ice bath for 30

- 21 -

several hours and filtered to collect a white crystalline solid which was dried under reduced pressure over Drierite to give 0.469 g of the title compound, mp: 230 °C (dec).

Anal. Calcd. for $C_6H_{10}N_4S$. HCl. 0.25 H_2O

5 Theory: % C, 31.69; % H, 5.06; % N, 24.65

Found: % C, 31.54; % H, 4.66; % N, 24.21

Example 3

1-(4-Methoxy-[1,2,5]thiadiazol-3-yl)piperazine Hydrochloride

10

The title compound of Example 1 (0.95 g, 3.9 mmol) was suspended in anhydrous methanol (10 mL) under a nitrogen atmosphere. Pellets of sodium metal (0.733 g, 32 g-atoms) were added slowly with stirring. An exotherm to reflux occurred. Heating under reflux was continued for 2 h in preheated oil bath. The reaction mixture was then cooled to room temperature and allowed to stir overnight. The volatiles were removed under reduced pressure and the mustard-colored residue was partitioned between ethyl acetate and water. The aqueous phase was extracted with ethyl acetate (3X). The organic phases were combined, dried ($MgSO_4$) and evaporated to give 0.268 g of a yellow oil. The oil was dissolved in methanol and treated with 1M HCl in ether (2.0 mL) to give a tan solid which was recrystallized from 1:2 isopropanol:isopropyl ether to give 89 mg of the title compound as mustard yellow crystals, mp: 190°C (dec).

Anal. Calcd. for $C_7H_{12}N_4OS$. HCl. 0.1 isopropanol

25 Theory: % C, 36.12; % H, 5.73; % N, 23.08.

Found: % C, 36.21; % H, 5.68; % N, 23.37.

- 22 -

Example 4

Cyclohexanecarboxylic acid { (1S)-1-benzyl-2-(4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}amide fumarate

5 N-BOC-L-phenylalanine (6 g, 22.6 mmol) was dissolved in methylene chloride (240 mL) under a nitrogen atmosphere. To this was added the compound of Example 1 (5.0 g, 20.7 mmol) followed by triethylamine (TEA, 2.1 g), HOBT (3.65 g), and dicyclohexylcarbodiimide (DCC, 4.7 g). The reaction mixture was allowed to stir at room temperature overnight. The reaction mixture was filtered to remove
10 insolubles and the volatiles was removed from the filtrate under reduced pressure. The residue was taken up in methylene chloride, cooled in a freezer, and filtered to remove a white solid. The filtrate was purified by chromatography on silica gel eluting with 0.4%-0.6% MeOH in methylene chloride to give Intermediate I ({1-benzyl-2-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]-2-oxo-ethyl}carbamic acid tert butyl ester) as an amorphous solid, mp: 45-51°C
15

Anal. Calcd. for $C_{20}H_{26}ClN_5O_3S$

Theory: % C, 53.15; % H, 5.80; % N, 15.49

Found: % C, 53.02; % H, 5.64; % N, 15.27

20 Intermediate I (2.0 g) was dissolved in dioxane (5 mL) and treated with 4 M HCl in dioxane under a nitrogen atmosphere overnight. A mass of white solid was observed. The reaction mixture was diluted with dioxane and filtered to collect the solid. After drying under reduced pressure, 1.57 g of (2S)-2-amino-1-[4(4-chloro-
25 [1,2,5]thiadiazol-3-yl)piperazin-1-]-3-phenylpropan-1-one hydrochloride [Intermediate II]: mp 201-205°C, was obtained.

Anal Calcd for $C_{15}H_{18}ClN_5OS \cdot HCl$. 0.45 dioxane

Theory: % C, 47.15; % H, 5.32; % N, 16.36

30 Found: % C, 47.03; % H, 5.35; % N, 15.88

- 23 -

Intermediate II (0.92 g, 2.6 mmol) was dissolved in anhydrous THF (30mL) under a nitrogen atmosphere. 1M BH₃ in THF (8.2 mL, 3 equivalents) was added (foaming) and the reaction mixture was heated under reflux 1 h. After cooling to 5 room temperature, 1N HCl (10 mL) was added cautiously and stirring was continued overnight at room temperature. After extracting with ether, the aqueous phase was chilled in an ice bath and adjusted to pH 14 with solid NaOH. A yellow oil separated which was extracted into ethyl acetate, dried (MgSO₄), filtered, and evaporated to give a thick yellow oil which was dried under reduced pressure to give 376 mg of 10 Intermediate III.

Intermediate III (357 mg, 1.06 mmol) was dissolved in anhydrous methylene chloride (20 mL) under a nitrogen atmosphere, followed by triethylamine (0.3 mL, 2 equivalents). Cyclohexylcarbonyl chloride (160 mg, 1 equivalent) was diluted with 15 methylene chloride (10 mL) and added dropwise at 0-5 C. The reaction mixture was allowed to warm to room temperature and was stirred overnight. The reaction mixture was quenched with sat. NaHCO₃ (10 mL) and sat. NaCl (10 mL). The organic phase was separated, washed with water (2X), and dried (MgSO₄). The solution was filtered and the volatiles were removed under reduced pressure to give a 20 viscous yellow oil was purified by flash column chromatography on silica gel eluting with up to 30% ethyl acetate in hexane to give 185 mg of the free base of the title compound. The compound was converted to the fumarate salt by treatment with fumaric acid in ethanol to give the title compound : mp, 138-140°C.

25 Anal Calcd for C₂₂H₃₀N₅ClOS . C₄H₄O₄

Theory: %C, 55.36; %H, 6.08; %N, 12.41

Found: %C, 55.08; %H, 5.96; %N, 12.14

- 24 -

Example 5

N-{(1S)-Benzyl-2-[4[(4-chloro-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}isonicotinamide

5 Intermediate III (120 mg, 0.35 mmol) was dissolved in methylene chloride (15 mL) under nitrogen. Isonicotinic acid (50 mg, 0.41 mmol) was added followed by triethylamine (0.08 mL), 1-hydroxybenzotriazole hydrate, HOBT, (55 mg), and dicyclohexylcarbodiimide, DCC, (85 mg). The reaction mixture was stirred at room temperature overnight. After filtration to remove solids, volatiles were removed from
10 the filtrate under reduced pressure. The residue was purified by flash column chromatography on silic gel eluting with methylene chloride to 2% methanol in methylene chloride to give the title compound, 100 mg, as a white solid. The free base was converted to the fumarate salt using fumaric acid in ethanol and isopropyl ether. An amorphous solid was obtained. mp: 99-125 °C.

15

Anal. Calcd. for $C_{21}H_{23}N_6ClOS \cdot 1.5 C_4H_4O_4 \cdot 0.75 H_2O$

Theory: %C, 51.38; %H, 4.97; %N, 13.05.

Found: %C, 51.63; %H, 4.77; %N, 12.43

20

Example 6

Pyridine-2-carboxylic acid { (1S)-1-benzyl-2,3-[4(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}amide

25 Example 6 was prepared using Intermediate III and pyridine-2-carboxylic acid according to the method of Example 5. The fumaric acid salt was a granular solid: mp 60-70°C

Anal Calcd. For $C_{21}H_{23}N_6ClOS \cdot C_4H_4O_4 \cdot 1 H_2O \cdot 0.2$ diisopropylether

Theory: %C, 52.67; %H, 5.36; %N, 14.07.

30 Found: %C, 52.89; %H, 5.05; %N, 13.59

- 25 -

Example 7

Cyclohexanecarboxylic acid { (2R)-1-benzyl-2-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}methylamide

5

The compound of Example 1 and BOC-protected N-methyl-D-phenylalanine were allowed to react according to the method of Example 4 to give Intermediate IV, { (1R)-1-benzyl-2-[4-(4-chloro-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]-2-oxoethyl}methylcarbamic acid tert-butyl ester : mp 109-111 C.

10

Intermediate IV was allowed to react with 4N HCl in dioxane according to the method of Example 4 to give Intermediate V, (2R)-1-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]-2-methylamino-3-phenylpropan-1-one: mp 230-232°C.

15

chloride (0.08 mL) in methylene chloride (1 mL) at room temperature. After stirring for 5 minutes, 2.5 N NaOH (5 mL) and brine (12 mL) were added. The organic phase was separated and the aqueous was extracted with brine (2X). The combined organic phases were dried ($MgSO_4$), evaporated and the residue was purified on silica gel eluting with 1% methanol in methylene chloride to give 185 mg of the title compound as an oil. (89%). The free base was converted to the fumaric acid salt: mp 51-59°C.

Anal Calcd for $C_{23}H_{32}N_5OSCl + 1.0 C_4H_4O_4 + 1.0 H_2O$

Theory: % C, 54.88; % H, 6.65; % N, 11.40.

25

Found: % C, 55.11; % H, 6.34; % N, 11.04.

Example 8**Cyclohexanecarboxylic acid { (1R)-1-benzyl-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)-piperazine-1-yl]ethyl}methyl amide**

5 Intermediate IV of Example 7 (2.20 g. 4.9 mmole) was dissolved in warm methanol (50 mL) with stirring. Sodium spheres were added portionwise keeping the reaction mixture at reflux and following the reaction by mass spec . When the reaction was complete, the volatiles were removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The aqueous phase was
10 separated, extracted with ethyl acetate and the organic phases were combined, dried (MgSO_4), filtered, and evaporated to give an oily residue. The residue was purified by chromatography on silica gel eluting with 0.5% to 0.75% methanol in methylene chloride to give Intermediate VI as a tacky foam. The foam was dissolved in anhydrous dioxane (20 mL), treated with 4 N HCl in dioxane (10 mL) and stirred at
15 ambient temperature for 5 h. Ethyl ether (15 mL) was added and Intermediate VII was collected by filtration (800 mg, 40%) as a white solid, mp: 237-239 C (dec).

20 Intermediate VII (726 mg, 1.82 mmol) was reduced with 1M BH_3 in THF (7 mL) containing TEA (0.3 mL) as described in Example 7. The crude product was purified by chromatography on silica gel eluting with 3.5% to 6% methanol in methylene chloride to give 398 mg (63%) of Intermediate VIII.

25 A solution of Intermediate VIII (298 mg, 0.86 mmol) in methylene chloride containing TEA (0.17 mL) was treated with a solution of cyclohexylcarbonyl chloride (0.17 mL) in methylene chloride (2 mL). After stirring for 15 minutes the reaction was quenched by the addition of brine (25 mL). The layers were separated and the aqueous phase was extracted twice with methylene chloride. The organic layers were combined, dried (MgSO_4), filtered, and evaporated to give a residue which was purified by chromatography on silica gel eluting with 0.5 % methanol in methylene chloride to give the title compound (252 mg, 64%) as an oil. The oil was dissolved in

ether, treated with ethereal HCl to give the HCl salt of the title compound as a white solid, mp: 190-193°C.

Anal. Calcd for $C_{24}H_{35}N_5O_2S + 1.00 HCl + 0.4 H_2O$

5 Theory: % C, 57.50; % H, 7.40; % N, 13.97.

Found: % C, 57.78; % H, 7.12; % N, 13.49.

Example 9

N-{1-Benzyl-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}-N-methylbenzamide

10 A solution of Intermediate VIII (100 mg, 0.29 mmol) in methylene chloride containing TEA (0.12 mL) was treated with a solution of benzoyl chloride (0.05 mL) in methylene chloride (1 mL). After stirring for 4 hours the reaction was quenched 15 by the addition of brine (10 mL). The layers were separated and the aqueous phase was extracted twice with methylene chloride. The organic layers were combined, dried ($MgSO_4$), filtered, and evaporated to give a residue which was purified by chromatography on silica gel eluting with 0.3-0.5 % methanol in methylene chloride to give the title compound (90 mg, 69%) as an oil. The oil was dissolved in ether, 20 treated with ethereal HCl to give the HCl salt of the title compound as a white solid, mp: 211-215°C.

Anal. Calcd. For $C_{24}H_{29}N_5O_2S + HCl$

Theory: %C, 59.06; %H, 6.2; %N, 14.35

25 Found: %C, 58.69; %H, 6.18; %N, 14.16

- 28 -

Example 10

Morpholine-4-carboxylic acid {1-benzyl-2-[4-(4-methoxy[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}methylamide

5 A solution of Intermediate VIII (100 mg, 0.29 mmol) in methylene chloride containing TEA (0.12 mL) was treated with a solution of morpholine carbonyl chloride (0.05 mL) in methylene chloride (1 mL). After stirring for 4 hours the reaction was quenched by the addition of brine (10 mL). The layers were separated and the aqueous phase was extracted twice with methylene chloride. The organic 10 layers were combined, dried (MgSO_4), filtered, and evaporated to give a residue which was purified by chromatography on silica gel eluting with 0.3-0.5 % methanol in methylene chloride to give the title compound (100 mg, 75%) as a waxy solid. The solid was dissolved in ether, treated with ethereal HCl to give the 2 HCl salt of the title compound as a white amorphous solid, mp: 68-97°C.

15

Anal. Calcd for $\text{C}_{22}\text{H}_{32}\text{N}_6\text{O}_3\text{S} + 2 \text{HCl}$

Theory: %C, 49.53; %H, 6.42; %N, 15.75

Found: %C, 49.74; %H, 6.66; %N, 15.64

20

Example 11

1-Methylcyclohexanecarboxylic acid { (1R)-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)-piperazin-1-yl]-1-pyridin-3-ylmethyl ethyl} amide

25 The compound of Example 1 was allowed to react with BOC-D-3-pyridylalanine according to the method of Example 1 to give Intermediate X, { (2R)-2-[4(4-chloro-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]-2-oxopyridin-3-ylmethyl ethyl}carbamic acid tert butyl ester as an amorphous solid.

Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{ClN}_6\text{O}_3\text{S}$

Theory: %C, 50.38; %H, 5.56; %N, 18.55

30 Found: %C, 51.25; %H, 5.65; %N, 18.18

- 29 -

The method of Example 4 was used to convert Intermediate X to Compound 11 with the exception that methylcyclohexylcarbonyl chloride was used in place of cyclohexanecarbonyl chloride.

5


Anal. Calcd for $C_{23}H_{34}N_6O_2S + 2 HCl + 0.33 H_2O$

Theory: %C, 51.40; %H, 6.87; %N, 15.64

Found: %C 51.38; %H, 6.90; %N, 15.21

CLAIMS:

1. A compound of the formula (1):



wherein:

the dotted line represents an optional bond;

two atoms of X, Y, or Z are nitrogen and the third atom is sulfur or oxygen;

R is H, halogen, OH, SH, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ thioalkyl, phenoxy, thiophenoxy, or phenyl, the phenyl ring being optionally substituted by from one to three substituents selected from C₁-C₆ alkyl; C₁-C₆ alkoxy; CF₃; Cl; Br; F; CN; or CO₂CH₃;


A is C, CH, or N;

R₁ is aryl, heteroaryl, or cycloalkyl groups, the aryl, heteroaryl or cycloalkyl groups being optionally substituted by from 1 to 3 substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy; CF₃, Cl, Br, F, CN, or CO₂CH₃;

R₂ is H or C₁-C₆ alkyl

R₃ is C₁-C₆ alkyl, aryl, 5- or 6-membered heteroaryl, C₃ to C₈ cycloalkyl optionally substituted by C₁-C₆ alkyl, or a 3 to 8-membered heterocyclic ring containing one or more heteroatoms selected from O, S or N, the aryl and 5- or 6-membered heteroaryl groups being optionally substituted by from one to three substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy, CF₃, Cl, Br, F, CN, or CO₂CH₃; or a pharmaceutically acceptable salt thereof.

2. A compound of Claim 1 having the formula (2):



wherein R, R₁, R₂, and R₃, are as defined in Claim 1; or a pharmaceutically acceptable salt thereof.

3. A compound as claimed in Claim 1 or Claim 2 wherein:

R is selected from H, halogen, OH, SH, C₁-C₆ alkyl, C₁-C₆ alkoxy, or C₁-C₆ thioalkyl;

R₁ is selected from aryl, heteroaryl, or cycloalkyl groups, optionally substituted by from 1 to 3 substituents selected from C₁-C₆ alkyl, C₁-C₆ alkoxy; CF₃, Cl, Br, F, CN, or CO₂CH₃;

R₂ is H or C₁-C₆ alkyl

R₃ is C₁-C₆ alkyl, optionally substituted aryl, optionally substituted 5- or 6-membered heteroaryl, C₃ to C₈ cycloalkyl optionally substituted by C₁-C₆ alkyl, or a 3 to 8-membered heterocyclic ring containing one or more heteroatoms selected from O, S or N;

or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 1 which is cyclohexanecarboxylic acid {(1S)-1-benzyl-2-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}amide or a pharmaceutically acceptable salt thereof.
5. A compound of Claim 1 which is N-{ (1S)-1-benzyl-2-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}isonicotinamide or a pharmaceutically acceptable salt thereof.
6. A compound of Claim 1 which is pyridine-2-carboxylic acid { (1S)-1-benzyl-2-[4-(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}amide or a pharmaceutically acceptable salt thereof.
7. A compound of Claim 1 which is cyclohexanecarboxylic acid {2R)-1-benzyl-2-[4[(4-chloro[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}methylamide or a pharmaceutically acceptable salt thereof.
8. A compound of Claim 1 which is cyclohexanecarboxylic acid { (1R)-1-benzyl-2-[4-(4-methoxy-[1,2,5]thiadizol-3-yl)piperazin-1-yl]ethyl}methylamide or a pharmaceutically acceptable salt thereof.
9. A compound of Claim 1 which is N-{ 1-benzyl-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}N-methylbenzamide or a pharmaceutically acceptable salt thereof.
10. A compound of Claim 1 which is morpholine-4-carboxylic acid { 1-benzyl-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)piperazin-1-yl]ethyl}methylamide or a pharmaceutically acceptable salt thereof.

- 33 -

11. A compound of Claim 1 which is 1-methylcyclohexanecarboxylic acid { (1R)-2-[4-(4-methoxy-[1,2,5]thiadiazol-3-yl)-piperazin-1-yl]-1-pyridin-3-ylmethyl ethyl} amide or a pharmaceutically acceptable salt thereof.


12. A pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

13. A method for treating depression in a mammal, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

14. A method for treating anxiety in a mammal, the method comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt thereof.

15. A process for preparing a compound of formula (1) as claimed in Claim 1 or a pharmaceutically acceptable salt thereof which comprises:

a) acylating a compound of formula (3)



(3)

wherein the dotted line R, R₁, R₂, X, Y, Z and A are as defined in claim 1, with a compound of formula:



- 34 -

(4)

or a reactive derivative thereof (e.g acid halide such as the chloride or a mixed anhydride) wherein R₃ is as defined in claim 1;

or

b) converting a basic compound of formula (1) to a pharmaceutically acceptable acid addition salt thereof.

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No

PCT/US 00/05240

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D285/10 C07D417/12 A61K31/41 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 462 638 A (AKZO) 27 December 1991 (1991-12-27) page 2, line 14 - line 41; claims; examples ---	1-15
A	WO 94 27996 A (NOVO NORDISK A/S) 8 December 1994 (1994-12-08) page 4, line 27 -page 5, line 10; claims; examples ---	1-15
A	US 4 539 318 A (BALDWIN ET. AL.) 3 September 1985 (1985-09-03) claims; examples ---	1-15
A	WO 97 34899 A (NOVO NORDISK A/S) 25 September 1997 (1997-09-25) claims; examples -----	1-15

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 June 2000

Date of mailing of the international search report

20.06.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Helps, I

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/05240

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 13 and 14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members			International Application No	
Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 462638	A	27-12-1991	AU 642369 B AU 7825291 A CA 2043604 A FI 912759 A JP 5140108 A NZ 238438 A PT 97903 A US 5135931 A ZA 9104204 A	14-10-1993 12-12-1991 12-12-1991 12-12-1991 08-06-1993 25-09-1992 31-03-1992 04-08-1992 25-03-1992
WO 9427996	A	08-12-1994	AU 6923894 A	20-12-1994
US 4539318	A	03-09-1985	ZA 8504157 A	29-01-1986
WO 9734899	A	25-09-1997	AU 2152497 A CA 2248153 A EP 0888355 A	10-10-1997 25-09-1997 07-01-1999